Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
JNJ-26854165 was originally developed as an activator of p53 capable of inducing apoptosis in cancer cell lines. In vitro, JNJ-26854165 demonstrated cytotoxic activity. The ALL cell line panel had a significantly lower median IC(50) (0.85 µM) than the remaining cell lines. In vivo JNJ-26854165 induced significant differences in EFS distribution compared to control in 18 of 37 solid tumors and in 5 of 7 of the evaluable ALL xenografts. Objective responses were observed in 4 of 37 solid tumor xenografts, and 2 of 7 ALL xenografts achieved PR or CR. Responses were noted in xenografts with both mutant and wild-type p53.
Smith, MA; Gorlick, R; Kolb, EA; Lock, R; Carol, H; Maris, JM; Keir, ST; Morton, CL; Reynolds, CP; Kang, MH; Arts, J; Bashir, T; Janicot, M; Kurmasheva, RT; Houghton, PJ
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)